Yahoo
    ASX - Delayed Quote AUD

    Immutep Limited (IMM.AX)

    0.0230 0.0000 (0.00%)
    At close: October 30 at 4:10:11 PM GMT+11
    Loading Chart for IMM.AX
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Immutep Quarterly Activities Report Q1 FY27

    Immutep Quarterly Activities Report Q1 FY27
    GlobeNewswire 2d ago
    Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

    Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
    GlobeNewswire 3mo ago
    Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

    Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
    GlobeNewswire 5mo ago
    Immutep Receives Nasdaq Notice of Bid Price Deficiency

    Immutep Receives Nasdaq Notice of Bid Price Deficiency
    GlobeNewswire 5mo ago
    Immutep Quarterly Activities Report Q3 FY26

    Immutep Quarterly Activities Report Q3 FY26
    GlobeNewswire 5mo ago
    Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

    Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
    GlobeNewswire 6mo ago
    Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma

    Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
    Insider Monkey 6mo ago
    Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

    Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
    GlobeNewswire 6mo ago
    Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

    Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
    GlobeNewswire 3mo ago
    Immutep Quarterly Activities Report Q4 FY26

    Immutep Quarterly Activities Report Q4 FY26
    GlobeNewswire 3mo ago
    Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

    Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
    GlobeNewswire 4mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: